Join our daily newsletter At The Bell to receive exclusive market insights
- Alterity Therapeutics (ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder
- The first patient has now received the first dosage in the company’s phase two clinical trial of ATH434 to treat early-stage multiple system atrophy
- The trial is expected to enrol around 60 patients and will see volunteers receive treatment for 12 months
- The study aims to provide an opportunity to detect changes in efficacy endpoints to optimise the design of a definitive phase three study
- Alterity Therapeutics last traded at 1.5 cents at 2:03 pm AEST
Alterity Therapeutics (ATH) has dosed its first patient in a clinical trial for a rare form of Parkinsonian disorder.
The first patient has now received the first dosage in the company’s phase two clinical trial of ATH434 to treat early stage multiple system atrophy (MSA), a highly debilitating disease.
While similar to Parkinson’s disease, MSA progresses more rapidly and causes profound disability, resulting in bladder dysfunction and the inability to maintain normal blood pressure, along with uncoordinated movements that contribute to falling.
The study will explore the effect of ATH434 treatment on imaging and protein biomarkers.
The trial is expected to enrol around 60 patients, and will see volunteers receive treatment for 12 months. This is hoped to provide an opportunity to detect changes in efficacy endpoints to optimise the design of a definitive phase three study.
Alterity’s Chief Executive Officer David Stamler said dosing of the first patient marks a significant milestone, as the company looks to bring a potential new treatment option to individuals living with MSA.
“This is just the first step as we expect to expand enrolment in multiple regions over the second half of this year,” David Stamler said.
Professor Tim Anderson, Lead Investigator of the trial at the New Zealand Brain Research Institute said he is glad to see investigation into this new treatment.
“As a clinician looking after people with MSA, I’m very pleased that Alterity has chosen to bring this clinical trial of a novel prospective therapy to New Zealand,” said Tim Anderson.
“There is presently no available treatment to slow down or prevent progression of this distressing brain disorder so trials such as this are very welcome.”
Alterity Therapeutics last traded at 1.5 cents at 2:03 pm AEST.
